Given that the action mechanism of PD1/PDL1 inhibitors is to block PD1/PDL interaction between tumor cells and immune cells (Figure 1), PDL1 expression status has served as a biomarker for predicting the treatment outcomes of patients receiving anti-PD1/PDL1 therapy. Here, CD274 is linked to neoplasm.